I first ran across a paper by Cosgrove et al in February [Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation] and have talked about it frequently. I think it’s an important article for a number of reasons: It’s about a contemporary medication, Vortioxetine [Brintellix® now Trintellix®]. Our Paxil Study 329 article and […]
Major depression is now recognized as a highly prevalent, chronic, recurrent and disabling biological disorder with high rates of morbidity and mortality. Indeed, major depression, which is projected to be the second leading cause of disability worldwide by the year 2020, is associated with high rates of mortality secondary to suicide and to the now […]
The first blog I encountered when I realized how much corruption there was in the medical literature was Health Care Renewal. It wasn’t about the psychiatric medications, but it was about the problem I was stirred up about at the time. I found others, but most of them had some underlying agenda of their own. […]
One feature of living here at the edge of the galaxy is frequent power outage – regular with storms, but sometimes they just happen. So I’ve got an XL battery backup for my computer. But every year or so, the big batteries go kerfunkle and need replacing. The replacements were on the floor next to […]
Note: The main article [Cipriani et al] is available full text on line at the time I’m writing this, but I can’t tell for how long. If pediatric depression is of any interest to you, I would recommend saving it to your computer/desktop as that access might disappear. Andrea Cipriani is an Oxford-based psychiatrist and […]
I expect most readers are as phobic about reading health care policy as I am. But about once a century, I try to look in on what’s happening – operating on the principle that if I don’t keep up a little, I can’t complain when it happens. This post is about the programs the Federal […]
Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression by L M Williams, C Debattista, A-M Duchemin, A F Schatzberg and C B Nemeroff Translational Psychiatry. (2016) 6, e799. Published online 3 May 2016 [full text on-line] Discussion Overall, the higher rate […]
In the last post [key opinion leaders: an example…], I said of Dr. Thase that "… most of us think of him not in any specific role as an expert professional, but rather as a Professional Expert" – implying that being a KOL is itself is a profession. And it’s the ability to lead the […]
you can’t learn it from books, you can’t learn it without books. …………………….zen saying… I grew up on the Tennessee River near Lake Chickamauga where I swam, picnicked, camped, boated, fished, skied, etc. Then I left for college and those things stayed with the lake. As an adult in Atlanta, I discovered Lake Sydney Lanier […]
Having become preoccupied with the newer antidepressant, Vortioxetine, I was going to talk some about the KOL’s [Key Opinion Leader] place in psychiatry using Michael Thase, one of the main such figures in the Vortioxetine story, as an example. But then I received a copy of an older article I’ve heard about but never seen. […]